# Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

> **NCT02824198** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 118 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** CYD Dengue Vaccine (5 dose formulation)
- **BIOLOGICAL:** Placebo, NaCl 0.9%

## Key facts

- **NCT ID:** NCT02824198
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2017-03-18
- **Final completion:** 2019-01-18
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824198, "Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02824198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*